AustralianSuper Pty Ltd Acquires 47,473 Shares of Boston Scientific Corporation $BSX

AustralianSuper Pty Ltd boosted its holdings in Boston Scientific Corporation (NYSE:BSX) by 1.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,746,328 shares of the medical equipment provider’s stock after purchasing an additional 47,473 shares during the period. Boston Scientific comprises about 1.2% of AustralianSuper Pty Ltd’s portfolio, making the stock its 12th largest holding. AustralianSuper Pty Ltd’s holdings in Boston Scientific were worth $268,124,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in shares of Boston Scientific by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock worth $14,729,575,000 after buying an additional 2,545,381 shares during the last quarter. State Street Corp raised its holdings in Boston Scientific by 1.1% during the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock worth $7,002,258,000 after acquiring an additional 713,379 shares in the last quarter. Geode Capital Management LLC boosted its position in Boston Scientific by 2.0% during the second quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock valued at $3,466,320,000 after purchasing an additional 622,602 shares during the last quarter. Norges Bank bought a new position in Boston Scientific in the second quarter valued at approximately $2,089,937,000. Finally, Invesco Ltd. increased its position in shares of Boston Scientific by 1.4% during the 2nd quarter. Invesco Ltd. now owns 16,851,518 shares of the medical equipment provider’s stock worth $1,810,022,000 after purchasing an additional 226,578 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Insider Activity at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the sale, the executive vice president owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. This trade represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares in the company, valued at $17,739,678.74. This trade represents a 21.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 80,204 shares of company stock worth $7,998,563 in the last ninety days. 0.50% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Oppenheimer cut their price objective on Boston Scientific from $125.00 to $100.00 and set an “outperform” rating for the company in a report on Friday, January 16th. Barclays increased their price target on shares of Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research note on Thursday, October 2nd. Weiss Ratings restated a “buy (b-)” rating on shares of Boston Scientific in a research note on Wednesday, January 21st. UBS Group reaffirmed a “buy” rating on shares of Boston Scientific in a report on Wednesday, December 17th. Finally, Leerink Partners lifted their price target on Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $123.89.

Boston Scientific Trading Up 0.1%

Shares of BSX stock opened at $93.74 on Thursday. Boston Scientific Corporation has a 12-month low of $85.98 and a 12-month high of $109.50. The company has a market capitalization of $138.96 billion, a PE ratio of 50.13, a price-to-earnings-growth ratio of 1.66 and a beta of 0.67. The firm has a 50 day moving average price of $95.36 and a two-hundred day moving average price of $99.65. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.